Medtronic PLC $MDT Shares Sold by Factory Mutual Insurance Co.

Posted by Brenda Bartman on Nov 4th, 2026

Factory Mutual Insurance Co. decreased its stake in Medtronic PLC (NYSE:MDT – Free Report) by 21.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 246,590 shares of the medical technology company’s stock after selling 66,900 shares during the quarter. Factory Mutual Insurance Co.’s holdings in Medtronic were worth $21,278,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of MDT. WCM Investment Management LLC purchased a new stake in Medtronic during the 1st quarter valued at $965,922,000. First Eagle Investment Management LLC lifted its position in Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after buying an additional 3,739,288 shares during the last quarter. Cullen Capital Management LLC purchased a new position in Medtronic during the second quarter worth $202,764,000. State Street Corp boosted its stake in Medtronic by 2.7% during the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after buying an additional 1,658,301 shares during the period. Finally, Amundi boosted its stake in Medtronic by 36.3% during the first quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after buying an additional 1,616,739 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on MDT shares. Barclays upgraded shares of Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 19th. Mizuho set a $115.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. UBS Group reaffirmed a “cautious” rating on shares of Medtronic in a research note on Wednesday, October 14th. Finally, BTIG Research cut their price target on shares of Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a report on Monday, October 12th. Eighteen analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $102.88.

View Our Latest Research Report on MDT

Medtronic Trading Down 0.3%

Shares of NYSE MDT opened at $98.95 on Wednesday. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The company has a market cap of $126.58 billion, a price-to-earnings ratio of 24.37, a PEG ratio of 2.32 and a beta of 0.56. The business’s 50 day moving average price is $91.94 and its 200-day moving average price is $88.36.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic’s revenue was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.98 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Insider Transactions at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president directly owned 42,186 shares in the company, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Geoffrey Martha sold 50,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the transaction, the chief executive officer directly owned 277,866 shares in the company, valued at $26,397,270. This represents a 15.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by insiders.

Medtronic Company Profile

(Free Report)

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.